HeartBeam (BEAT) Expected to Release Quarterly Earnings on Thursday

HeartBeam (NASDAQ:BEAT) is projected to release its Q2 2026 results after the market closes on Thursday, August 13th. Analysts expect the company to post earnings of ($0.10) per share and revenue of $0.1470 million for the quarter. Individuals can check the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Thursday, August 13, 2026 at 4:30 PM ET.

HeartBeam (NASDAQ:BEAT) last issued its quarterly earnings data on Wednesday, May 13th. The medical research company reported ($0.12) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.02. On average, analysts expect HeartBeam to post $-0 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

HeartBeam Stock Up 4.8%

Shares of BEAT stock opened at $0.55 on Tuesday. HeartBeam has a 12 month low of $0.48 and a 12 month high of $4.00. The company has a market cap of $30.46 million, a PE ratio of -0.98 and a beta of -0.78. The business’s 50 day moving average is $0.65 and its two-hundred day moving average is $1.01.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. CIBC Private Wealth Group LLC acquired a new position in shares of HeartBeam in the 4th quarter valued at $26,000. Geode Capital Management LLC increased its stake in HeartBeam by 4.1% in the fourth quarter. Geode Capital Management LLC now owns 305,740 shares of the medical research company’s stock valued at $734,000 after acquiring an additional 12,142 shares during the period. Raymond James Financial Inc. raised its position in HeartBeam by 102.2% in the second quarter. Raymond James Financial Inc. now owns 28,178 shares of the medical research company’s stock worth $35,000 after purchasing an additional 14,242 shares in the last quarter. Jane Street Group LLC acquired a new position in HeartBeam in the fourth quarter worth about $55,000. Finally, Virtu Financial LLC bought a new position in HeartBeam during the fourth quarter worth about $70,000. 7.77% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on BEAT. Weiss Ratings reiterated a “sell (e+)” rating on shares of HeartBeam in a research note on Thursday, July 2nd. HC Wainwright decreased their target price on HeartBeam from $5.50 to $2.50 and set a “buy” rating for the company in a research note on Friday, May 22nd. Maxim Group initiated coverage on HeartBeam in a report on Tuesday, July 14th. They issued a “buy” rating and a $2.00 target price on the stock. D. Boral Capital cut HeartBeam from a “buy” rating to a “hold” rating in a research report on Monday, April 20th. Finally, Benchmark lowered their price objective on shares of HeartBeam from $8.00 to $5.00 and set a “speculative buy” rating on the stock in a research note on Friday, May 15th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $4.00.

About HeartBeam

BioTelemetry, Inc, a remote medical technology company, provides remote cardiac monitoring, remote blood glucose monitoring, centralized core laboratory services for clinical trials, and original equipment manufacturing services for healthcare and clinical research customers worldwide. It operates in two segments, Healthcare and Research. The Healthcare segment focuses on the remote cardiac monitoring to identify cardiac arrhythmias or heart rhythm disorders. This segment offers mobile cardiac telemetry services; and event monitoring services, which enable physicians to prescribe wireless event, digital loop event, memory loop event, memory loop event, and non-loop event monitors.